Home Online Features U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
U.S. FDA Removes Clinical Hold on Novavax’s COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Hand-out
Press Releases
Novavax, Inc.  
November 11, 2024

U.S. FDA Removes Clinical Hold on Novavax’s COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

GAITHERSBURG, Md., Nov. 11, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social